Budget impact of introducing tildrakizumab for the treatment of moderate to severe plaque psoriasis in the United States

Carrico, J., Zhao, Y., Jia, X., Brodtkorb, T-H., A, M., & Lowry, S. (2018). Budget impact of introducing tildrakizumab for the treatment of moderate to severe plaque psoriasis in the United States. Journal of managed care & specialty pharmacy, 24(10-a Suppl), S78-S79. https://doi.org/10.18553/jmcp.2018.24.10-a.s1

Abstract


Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Epigenetic biomarkers for smoking cessation
Article

A pilot PT scheme for external assessment of laboratory performance in testing synthetic opioid compounds in urine, plasma, and whole blood
Article

The effects of exposure to road traffic noise at school on central auditory pathway functional connectivity